Scarica l'app Stockscreener
31.82
1.73%
0.54
Dopo l'orario di chiusura:
31.84
0.02
+0.06%
Precedente Chiudi:
$31.28
Aprire:
$31.33
Volume 24 ore:
222.29K
Relative Volume:
0.64
Capitalizzazione di mercato:
$3.89B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+16.51%
1M Prestazione:
+10.49%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$30.23
$31.97
Intervallo di 1 settimana:
$27.36
$33.15
Portata 52W:
$24.51
$34.47
Parabilis Medicines Inc Stock (PBLS) Company Profile
Nome
Parabilis Medicines Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare PBLS vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PBLS
Parabilis Medicines Inc
|
31.82 | 3.83B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Parabilis Medicines Inc Borsa (PBLS) Ultime notizie
Parabilis Medicines, Inc. Revenue Breakdown – NASDAQ:PBLS - TradingView
PBLS|Parabilis Medicines Ord Shs|Price:31.280|Chg%:-1.530 - TradingKey
Scribe secures $129M in a rare gene editing IPO - BioPharma Dive
Parabilis Medicines(PBLS.US) 10% Shareholder Buys US$6.92 Million in Common Stock - Moomoo
Form 4 Parabilis Medicines For: 22 July - Investing.com India
Form 4 Parabilis Medicines For: 22 July By Investing.com - Investing.com South Africa
Parabilis Medicines, Inc. (PBLS) Revenue (TTM) - Zacks Investment Research
RA Capital boosts stake in Parabilis Medicines (PBLS) with stock buys - Stock Titan
Parabilis Medicines (PBLS) 10K Form and Latest SEC Filings 2026 - MarketBeat
Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021 - BioWorld News
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
LifeSci Capital Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $42 - Moomoo
With record listing prices, what the mid-year IPO market says about the current state of biopharma - The Pharma Letter
Primary Markets Group June 2026 U.S. IPO Update - Seeking Alpha
Parabilis Medicines, Inc. (NASDAQ:PBLS) Sees Significant Increase in Short Interest - MarketBeat
PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart - mexc.co
Parabilis Medicines, Inc.'s Quiet Period Set To Expire on July 20th (NASDAQ:PBLS) - MarketBeat
Teresa Jurgensen Net Worth (2026) - GuruFocus
Thomas Rodolpho Kotarakos Net Worth (2026) - GuruFocus
Helen Huei In Ho Net Worth (2026) - GuruFocus
Soleus Capital Management, L.p. Net Worth (2026) - GuruFocus
Soleus Pe Gp Iii, Llc Net Worth (2026) - GuruFocus
Soleus Gp, Llc Net Worth (2026) - GuruFocus
Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PBLS Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Mohammed Fawzi Benzaghou Net Worth (2026) - GuruFocus
Parabilis Medicines (NASDAQ:PBLS) Rating Increased to Hold at Zacks Research - MarketBeat
PBLS|Parabilis Medicines Ord Shs|Price:29.510|Chg%:-0.840 - TradingKey
This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
Leerink Partners Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $40 - Moomoo
A Quick Look at Today's Ratings for Parabilis Medicines(PBLS.US), With a Forecast Between $40 to $45 - Moomoo
Leerink initiates Parabilis Medicines stock with Outperform rating By Investing.com - Investing.com South Africa
BofA Securities initiates Parabilis Medicines stock coverage with buy rating By Investing.com - Investing.com Nigeria
The biggest biotech funding rounds in June 2026 - Labiotech.eu
PBLS Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Parabilis Medicines Price Target Announced at $40.00/Share by Guggenheim - Moomoo
Analyst Initiates Buy on Parabilis, Citing First-in-Class Wnt Inhibitor Zolucatidine and Strong Cash Runway - TipRanks
Michael Schmidt Initiates Buy on Parabilis Medicines, Citing Helicon Platform and Zolucatetide as Key Value Drivers with $40 Price Target - TipRanks
BofA Securities initiates Parabilis Medicines stock coverage with buy rating - Investing.com
Leerink initiates Parabilis Medicines stock with Outperform rating - Investing.com
Guggenheim initiates Parabilis Medicines stock with buy rating By Investing.com - Investing.com Nigeria
Guggenheim initiates Parabilis Medicines stock with buy rating - Investing.com
Large VC financings improve in H1 2026 - BioWorld News
Nasdaq Delivers the Strongest First Half in U.S. Exchange History as Public Markets Momentum Builds - Moomoo
Mass. biotech IPO proceeds near $3.2B, close in on pandemic-era record pace - The Business Journals
Insider Stock Purchases: June 29, 2026 - Quiver Quantitative
[Form 4] Parabilis Medicines, Inc. Insider Trading Activity - Stock Titan
Parabilis Medicines (PBLS) holder reports 527,070-share Series F position - Stock Titan
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested - Yahoo Finance
Price to earnings forward of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
Price to book forward of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
Parabilis Medicines Inc Azioni (PBLS) Dati Finanziari
Non sono disponibili dati finanziari per Parabilis Medicines Inc (PBLS). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):